On 14 Jan 2020, Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) spotted trading -36.42% off 52-week high price. On the other end, the stock has been noted 176.39% away from the low price over the last 52-weeks. The stock changed -5.11% to recent value of $18. The stock transacted 256367 shares during most recent day however it has an average volume of 343.46K shares. The company has 23.72M of outstanding shares and 17.98M shares were floated in the market.
Mirum Pharmaceuticals, Inc. (MIRM) recently stated financial results for the quarter ended September 30, 2019, and provided an update on its clinical programs.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, recently stated financial results for the quarter ended September 30, 2019, and provided an update on its clinical programs.
“The first nine months of 2019 have seen great progress toward bringing maralixibat to market for Alagille syndrome and progressive familial intrahepatic cholestasis,” stated Chris Peetz, president and chief executive officer of Mirum. “The granting of breakthrough designation by the Food & Drug Administration and an oral late breaking presentation at the Liver Meeting are testimony of the tremendous potential of maralixibat for Alagille syndrome. The next 12 months are poised to be a transformational year as we prepare for commercialization and complete the MARCH-PFIC Phase 3 study.”
Third Quarter 2019 Financial Results
For the quarter ended September 30, 2019, Mirum stated a net loss of $15.1M.
Total operating expenses for the quarter ended September 30, 2019, were $15.9M.
Research and development expenses for the third quarter of 2019 were $12.2M.
General and administrative expenses during the quarter ended September 30, 2019, were $3.7M.
As of September 30, 2019, Mirum had cash, cash equivalents and investments of $153.6M.
The price moved ahead of -16.77% from the mean of 20 days, 35.95% from mean of 50 days SMA and performed 49.63% from mean of 200 days price. Company’s performance for the week was -20.53%, 114.29% for month and YTD performance remained -26.59%.